FilingReader Intelligence
Maccura gains new product certificates, adjusts equity plans
June 16, 2025 at 12:30 PM UTC•By FilingReader AI
Maccura Biotechnology (SZSE:300463) announced the receipt of registration certificates for several new in-vitro diagnostic reagents, including kits for testing anti-cardiolipin antibodies (IgA, IgG, IgM) using direct chemiluminescence. These reagents will be used to assist diagnosis of antiphospholipid syndrome and systemic lupus erythematosus.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Announcement on Termination of Implementation of 2024 Restricted Stock Incentive Plan and Repurchase and Cancellation of Class I Restricted Stocks and Cancellation of Class II Restricted StocksJune 11, 2025 at 08:00 AM UTC
Announcement on the transfer of all equity interests in a holding subsidiaryJune 11, 2025 at 08:00 AM UTC
Announcement on Reducing Registered Capital and Amending the Articles of AssociationJune 11, 2025 at 08:00 AM UTC
News Alerts
Get instant email alerts when Maccura Biotechnology publishes news
Free account required • Unsubscribe anytime